InveniAI Featured in The Guardian’s Rare Disease Campaign to Showcase how Artificial Intelligence can be Leveraged to Create Patient Solutions
01 mars 2019 09h00 HE
|
InveniAI
GUILFORD, Conn., March 01, 2019 (GLOBE NEWSWIRE) -- InveniAI® Corporation, a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform...
ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day
29 janv. 2019 08h30 HE
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands & CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative...
ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10
07 janv. 2019 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
ProQR to Host R&D Day in New York on January 29
03 janv. 2019 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) will host a Research & Development Day for investors on Tuesday, January 29 at...
ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2
02 janv. 2019 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10
17 déc. 2018 11h52 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
ProQR Announces Strategic Changes to the Management Team and Key New Hires
13 déc. 2018 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 13, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10
10 déc. 2018 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 10, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative...
ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients
04 déc. 2018 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
ProQR to Present at the Evercore ISI HealthConX Conference
20 nov. 2018 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Nov. 20, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...